15.47
-0.07(-0.45%)
Currency In USD
| Previous Close | 15.54 |
| Open | 15.54 |
| Day High | 15.97 |
| Day Low | 14.97 |
| 52-Week High | 16 |
| 52-Week Low | 1.01 |
| Volume | 4.97M |
| Average Volume | 5.56M |
| Market Cap | 4.79B |
| PE | -35.98 |
| EPS | -0.43 |
| Moving Average 50 Days | 9.57 |
| Moving Average 200 Days | 3.88 |
| Change | -0.07 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $887.55 as of March 07, 2026 at a share price of $15.47. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $4,497.09 as of March 07, 2026 at a share price of $15.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
GlobeNewswire Inc.
Mar 05, 2026 12:01 PM GMT
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Na
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca’s diversified IP portfolio for RAS-driven cancers Initial Phase 1 monotherapy data expected for ERAS-0015 in 1H and
Erasca to Present at Upcoming Conferences in February
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to